| Project/Area Number |
16K11681
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Surgical dentistry
|
|---|
| Research Institution | Gifu University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
柴田 敏之 岐阜大学, 大学院医学系研究科, 教授 (50226172)
牧田 浩樹 岐阜大学, 大学院医学系研究科, 講師 (50345790)
|
|---|
| Project Period (FY) |
2016-04-01 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2018: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Keywords | 口腔ガン / 4nqo舌癌ラットモデル / PD-1／PD-L1経路 / 4NQO舌癌ラットモデル / PD-1/PD-L1経路 / PDーL１ / PD-L1 / 口腔発がんモデル / 口腔がん / 4NQOラット / PD-1/PD-L1 |
|---|
| Outline of Final Research Achievements |
Nivolumab has been sold in japan.Although adaptation to oral cancer has been expanded,PD-1/PD-L1 pathway In oral carcinogenesis was still unknown.We aimed to analyze the abnormal expression of PD-L1 in 4NQO induced rat tongue cancer model.We used resection specimens of rat tongue cancer model and measured the expression level of PD-L1.We demonstrated that the control group was not observed PD-L1 expression, but abnormal expression of PD-L1 in tongue cancer group
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究により、4NQO誘発ラット舌癌モデルにおけるPD-L1の発現異常を明らかにした。今研究の結果は、今後更に発展すると思われる免疫療法の分野において、動物モデルで確認することも可能となり、口腔癌治療に有効な口腔発癌抑制物質の新たな開発につながるものと考えられ、意義は非常に高いと考える。
|
